AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03786783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Given IV
Study NCT03786783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT03786783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT03786783 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study NCT03786783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given PO
Study NCT03786783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT03786783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study NCT03786783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV
Study NCT03786783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Given IV
Study NCT03786783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT02236299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right Coronary Artery Percutaneous Coronary Intervention
Study NCT02236299 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Right Coronary Artery Percutaneous Coronary Intervention
Study NCT02236299 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline placebo infusion
Description: 30 minute placebo infusion used as a comparator to the GLP-1 infusion
Study NCT02236299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-1 Infusion
Description: 30 minute infusion GLP-1
Study NCT03966027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative protocol (Immediate weight bearing)
Description: After ORIF of the ankle fracture, the patient will be randomized to follow an immediate weight bearing rehabilitation protocol using an offloading hindfoot brace
Study NCT03966027 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Postoperative Protocol (Delayed Weight Bearing)
Description: After ORIF of the ankle fracture, the patient will be randomized to follow a standard delayed weight-bearing rehabilitation protocol
Study NCT03171233 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization with movement
Description: Participants Mobilization Group with Movement are positioned knee facing the physiotherapist, are not elastic passages above the participant's malleolus and are from the physiotherapist's pelvis. The therapist applies a posterolateral slip sustained to a tibia through the belt, leaning backward, while the talus and forefoot are secured with the space between the thumb and the second finger of the hand of both hands. The participant will be instructed to perform a slow dorsiflexion movement for their maximum amplitude.
Study NCT03171233 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self mobilization with movement
Description: In the Auto Mobilization with Movement group, participants will self-mobilize the ankle on top of a box (15 centimeters with a 10 ° incline), a non-elastic band will pass below the malleoli and the back of the band will be placed in the middle of the other Lower limb, thus mobilizing the talus in the posteroinferior direction, the participant should maintain the force in that direction while making the dorsiflexion movement in closed kinetic chain until returning to the initial position again. Using the same group protocol as the therapist will help.
Study NCT00588042 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood pressure cuff
Description: Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes
Study NCT00588042 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: blood pressure cuff
Description: 3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia
Study NCT02780037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regulatory frame: prevention
Description: Exercise program presented as preventing deterioration.
Study NCT02780037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regulatory frame: promotion
Description: Exercise program presented as promoting improvement.
Study NCT02780037 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Regulatory frame: not implied
Description: Exercise program presented without implied consequences.
Study NCT02629315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carnoy's solution
Study NCT02629315 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10% neutral buffered formaldehyde
Study NCT01082328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuvan®
Description: Kuvan® (sapropterin dihydrochloride) oral solution 20 milligram per kilogram (mg/kg) will be given once daily for 28 +/- 1 days.
Study NCT03131752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elastic Resistance Intervention in Exacerbated Patients
Description: The intervention protocol will performed during 7 days for all patients and this will begin 24 -48 hours after the start of medication for exacerbation. Those who are hospitalized and discharged before this period will continue their treatment at the Laboratory of Spirometry and Respiratory Physiotherapy (LEFIR) of the Federal University of São Carlos. The intervention will also perform for at least 5 continuous days. The ideal elastic band for the training will be chosen through the test of 10 maximum repetitions. The test and the training will be performed in an ergonomic chair allowing the lower limbs to remain pending. After 24 hours of the test, patients will perform knee extension exercise with the appropriate elastic band. Three sets of 10 repetitions will be done in each exercise, with a minimum rest interval of 1 minute between sets or until heart rate values return to baseline. Patients will be re-evaluated 1 and 3 months after the first contact.
Study NCT00857675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAAA
Description: Adefovir Dipivoxil (12 weeks) + open lable Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260weeks)
Study NCT00857675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAPA
Description: Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + placebo (12 weeks) + open label-Adefovir Dipivoxil (52-260 weeks)
Study NCT00857675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AAPA
Description: Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + placebo (12 weeks) + open label-Adefovir Dipivoxil (52-260 weeks)
Study NCT00857675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAAA
Description: Placebo (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260 weeks)
Study NCT00857675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PAAA
Description: Placebo (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260 weeks)
Study NCT02699346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HS-1000 recording
Study NCT04095377 — intervention group
Intervention type: OTHER
Intervention: No intervention, this is a retrospective study.
Description: No intervention, this is a retrospective study.
Study NCT00896701 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study NCT00842088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule. Administered orally once a day on dosing days.
Study NCT03649568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pork
Description: 1 oz lean pork
Study NCT03649568 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Egg
Description: 1 large whole egg
Study NCT03649568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black beans
Description: 0.5 cups cooked black beans
Study NCT03649568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almonds
Description: 1 oz almonds
Study NCT02571491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: 50 mg/ml, IV (in the vein) during surgery operation, followed by IV ketamine hydrocloride perfusion 2mcg/Kg/min before and until 72 hours after operation Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT02571491 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg/ml, IV (in the vein) during surgery operation, followed by IV placebo perfusion 2mcg/Kg/min before and until 72 hours after operation
Study NCT02571491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: at doses of 0.3 mcg / kg / min during and until the end of the surgical operation
Study NCT02571491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: at doses of 0.3 mcg / kg / min during and until the end of the surgical operation
Study NCT02571491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride
Description: at the dose of 150 mcg / kg, 60 minutes before the extubation procedure and until 72 hours after operation by intravenous infusion
Study NCT02571491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine hydrochloride
Description: at the dose of 150 mcg / kg, 60 minutes before the extubation procedure and until 72 hours after operation by intravenous infusion
Study NCT02607046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: The exercise program includes supervised and home-based walking and strength exercise.
Study NCT02607046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMES
Description: This intervention consists of using neuromuscular electrical stimulation (NMES) as a form of passive exercise for muscles in the legs.
Study NCT01211834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks
Study NCT01211834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARDs
Description: Methotrexate(MTX) and/or 1 DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)
Study NCT01211834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenously over 1 hour infusion every 4weeks
Study NCT01211834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DMARDs
Description: Methotrexate(MTX) and/or 1 DMARDs
Study NCT00842088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HQK-1001
Description: HQK-1001 capsules. 10 mg/kg, 20 mg/kg or 30 mg/kg administered once a day on dosing days.
Study NCT04462133 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Dual-priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR)
Description: Empirical H. pylori eradication treatment versus tailored therapy based on DPO-PCR results
Study NCT04462133 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dual-priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR)
Description: Empirical H. pylori eradication treatment versus tailored therapy based on DPO-PCR results
Study NCT00789568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapropterin dihydrochloride
Description: 20 mg/kg and 100 mg/kg
Study NCT00789568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin is included as a positive control to demonstrate the assay sensitivity based on the expected increased QTc response.
Study NCT00789568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin placebo
Description: Moxifloxacin placebo tablet
Study NCT00789568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin placebo
Description: Moxifloxacin placebo tablet
Study NCT04427930 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JOINTSTEM
Description: Autologous Adipose Tissue derived MSCs
Study NCT01176474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 157-165 (165V)
Description: The vaccine contains two peptides from two different proteins (peptides are pieces that make up proteins) called gpl00 and NY-ES0-1.~Route of Administration: When prepared as a vaccine emulsion with Montanide ISA 51 VG, the vaccine is given by deep subcutaneous injection.~Method of Administration: The 0.5 mg vaccine emulsion dose is administered as a 1 mL injection (0.5 mg/1 mL) as a deep subcutaneous injection in the anterior thigh of the same extremity. Injections should be separated by at least 3 cm to avoid the formation of coalescent granulomas. All 4 peptides (total of 6 injections) will be administered in the same thigh and alternating thighs will be used for each subsequent treatment.
Study NCT01176474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (BMS-936558) is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1).~Nivolumab will be given at the following dosages: 1, 3, or 10 mg/kg.~Nivolumab will be administered as an i.v. infusion, using a volumetric pump with a 0.2 micron in-line filter at the protocol-specified dose(s) and rate.
Study NCT01176474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100:280-288 (288V)
Description: The vaccine contains two peptides from two different proteins (peptides are pieces that make up proteins) called gpl00 and NY-ES0-1.~Route of Administration: When prepared as a vaccine emulsion with Montanide ISA 51 VG, the vaccine is given by deep subcutaneous injection.~Method of Administration: The 0.5 mg vaccine emulsion dose is administered as a 1 mL injection (0.5 mg/1 mL) as a deep subcutaneous injection in the anterior thigh of the same extremity.
Study NCT01176474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 vegetable grade (VG)
Description: Route of Administration: Administer peptide vaccine emulsions prepared with Montanide® ISA 51 VG by deep subcutaneous injection.~Method of Administration: Divide peptide vaccine emulsion dose volumes of greater than 1.5 mL into 2 or more injections. Administer injections typically into the anterior thigh deep subcutaneous tissue. Perform subsequent injections in rotating sites. Use a 20 or 21 gauge needle for deep subcutaneous injection of the peptide vaccine emulsion.
Study NCT01176474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be given at the following dosage: 3 mg/kg.~Ipilimumab will be administered as an i.v. infusion, using a volumetric pump with a 0.2 micron in-line filter at the protocol-specified dose(s) and rate.
Study NCT01176474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis Procedure
Description: Some blood will be removed from the participant's veins and processed by a machine to remove a small portion of the white cells. The rest of the blood will be returned into their veins. This procedure is called apheresis. Apheresis is done to collect cells to allow the investigators to understand how their immune system is functioning before and after receiving nivolumab and vaccine. This will be done for research purposes only. The red cells and blood clotting cells will not be permanently removed during this procedure. White blood cells will need to be removed by apheresis before participants receive the study drug.
Study NCT00247130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Study NCT00247130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranitidine
Study NCT02235337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin 400mg daily
Study NCT01585831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel 1%
Description: Testosterone gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist after reviewing labs.
Study NCT01585831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: The placebo gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist.
Study NCT01921036 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional cardiac rehabilitation
Description: mutifactoral cardiac rehabilitation
Study NCT01921036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined exercise
Description: Moderate endurance and resistance exercise once a week over six months
Study NCT00517257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 mg orally once daily for 24 weeks
Study NCT00517257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet orally once daily for 24 weeks
Study NCT02494310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Resolution Microendoscopy Imaging
Description: Innovative technique to evaluate epithelial cell morphology in situ. The device is not invasive and does not exchange energy with human body.
Study NCT04123483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EnBrace HR Softgel
Description: Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 8 week study
Study NCT01238211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT01238211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT01238211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT01238211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03496207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03496207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
Study NCT03496207 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SOC
Description: SOC therapy refers to approved PAH-specific medications and may consist of monotherapy or combination therapy with endothelin-receptor antagonists, phosphodiesterase 5 (PDE5) inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogues or receptor agonists.
Study NCT03496207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC
Description: SOC therapy refers to approved PAH-specific medications and may consist of monotherapy or combination therapy with endothelin-receptor antagonists, phosphodiesterase 5 (PDE5) inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogues or receptor agonists.
Study NCT02394600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grastek®
Description: one tablet daily for four months
Study NCT04396951 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active external overheating with heating plate, Aragonia ® MTC 400
Description: It is a heating device that is adjustable in height up to 50 cm from the patient and generates radiant heat at low temperature (up to 39 ◦C) distributed evenly. It is equipped with an adjustable 0-9 potentiometer and has a skin temperature probe as a control and safety mechanism Measure during 6 hours with indirect calorimetry in first week
Study NCT04325061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily from Day 6 to 10 of randomization
Study NCT04155957 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rapid Recovery Rehabilitation Programme
Description: Usual intervention at Hospital Clínic de Barcelona for post-operative rehabilitation of TKA patients. Participants, already at home after hospital discharge, must perform 5 different exercises 4 times a day (twice in the morning, twice in the afternoon).~Participants are also encouraged to walk and stretch their legs. Domiciliary visits by a physiotherapist start at approximately 2 weeks after the surgery to help participants do the exercises.
Study NCT04396951 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active external overheating with air blanket, Equator Level 1® de Smiths Medical
Description: Composed of a unit that produces hot air and forced air adjustable from 38ºC to 43ºC. Sends hot forced air distributed by tubular blanket that convectively heats the patient by diffusing hot air directed at the patient through the textile pore of the air blanket Measure during 6 hours with indirect calorimetry in first week
Study NCT00680316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dornase alfa
Description: 2.5 mL (2.5 mg) dornase alfa nebulized once daily for 16 (+/-2) days
Study NCT00680316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2.5 mL (2.5 mg) placebo nebulized once daily for 16 (+/-2) days